Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Race Oncology Ltd banner

Race Oncology Ltd
ASX:RAC

Watchlist Manager
Race Oncology Ltd Logo
Race Oncology Ltd
ASX:RAC
Watchlist
Price: 2.15 AUD -4.44% Market Closed
Market Cap: AU$384.1m
Write Note Create Alert Ask AI

Race Oncology Ltd
Investor Relations

Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.

Show more
Loading
RAC
S&P/ASX 300
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Peter M. Smith Ph.D.
Executive Chairman
No Bio Available
Dr. Daniel Tillett
CEO, Managing Director & Director
No Bio Available
Dr. Michelle Rashford
Chief Medical Officer
No Bio Available
Mr. Brendan Brown
Chief Financial Officer
No Bio Available
Dr. Sophia Moscovis
Vice President of Operations & Strategy
No Bio Available
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.
Company Secretary
No Bio Available

Contacts

Address
NEW SOUTH WALES
Sydney
Level 36, Gateway 1, Macquarie Place
Contacts
+61280513043.0
www.raceoncology.com
sparklesyt

See Also

Summary
RAC intrinsic value, competitors valuation, and company profile.
DCF Valuation
RAC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RAC stock valuation using valuation multiples.
Wall Street Estimates
RAC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RAC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 317,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.